Springworks Therapeutics ( (SWTX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
SpringWorks Therapeutics has recently experienced significant stock movements due to its strategic collaboration with Jennifer Fisher to advance treatment options for desmoid tumors. This partnership is expected to increase the company’s influence in this specialized market. Adding to the momentum, major financial institutions BofA and Wedbush have raised their price targets for SpringWorks. BofA’s optimism stems from the company’s growth potential, while Wedbush foresees a potential offer from Merck KGaA that could further boost SpringWorks’ valuation.
More about Springworks Therapeutics
YTD Price Performance: 56.04%
Average Trading Volume: 1,869,391
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.19B
For further insights into SWTX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.